ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CTLT Catalent Inc

55.81
-0.17 (-0.30%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Catalent Inc NYSE:CTLT NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.17 -0.30% 55.81 56.115 55.69 56.06 1,604,330 22:30:00

Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast

26/01/2024 6:35pm

Business Wire


Catalent (NYSE:CTLT)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Catalent Charts.

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Catalent invites all interested parties to listen to the webcast and view a supplemental slide presentation, both of which will be accessible through Catalent’s website at https://investor.catalent.com. The webcast replay, along with the supplemental slides, will be available for 90 days at https://investor.catalent.com.

About Catalent

Catalent, Inc., is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.

Investor Contact: Paul Surdez, Catalent, Inc. (732) 537-6325 investors@catalent.com

1 Year Catalent Chart

1 Year Catalent Chart

1 Month Catalent Chart

1 Month Catalent Chart

Your Recent History

Delayed Upgrade Clock